Literature DB >> 31740765

Does use of biosimilar G-CSF change plerixafor utilization during stem cell mobilization for autologous stem cell transplant?

Nadine Abdallah1, Seongho Kim2, Lois Ayash2, Scott Klimecki3, Marie Ventimiglia3, Asif Alavi2, Voravit Ratanatharathorn2, Joseph Uberti2, Abhinav Deol4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31740765      PMCID: PMC7231668          DOI: 10.1038/s41409-019-0744-5

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  2 in total

1.  Zarxio (Filgrastim-sndz): The First Biosimilar Approved by the FDA.

Authors:  Mina Awad; Pavit Singh; Olga Hilas
Journal:  P T       Date:  2017-01

2.  Zarxio (Filgrastim-sndz): First Biosimilar Approved in the United States.

Authors:  Lisa A Raedler
Journal:  Am Health Drug Benefits       Date:  2016-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.